Q2 2024 Heartbeam Inc Earnings Call Transcript
Key Points
- HeartBeam Inc (BEAT) is developing AIMIGo, a credit card-sized, cable-free cardiac monitoring device capable of producing a 12-Lead ECG.
- The company has broad IP protection on its core technology, including novel form factors like extended wear cardiac monitors and mobile cardiac telemetry devices.
- HeartBeam Inc (BEAT) is making steady progress on regulatory milestones, with the initial 510(k) submission for AIMIGo under active FDA review.
- The company has completed enrollment in the VALID-ECG study, which will support further FDA submissions.
- HeartBeam Inc (BEAT) has presented positive data on its AI algorithms, demonstrating superior performance in detecting atrial flutter compared to traditional methods.
- General and administrative expenses increased to $2.2 million in Q2 2024 from $1.8 million in Q2 2023, primarily due to noncash stock-based compensation and higher consulting costs.
- Research and development expenses rose to $2.8 million in Q2 2024 from $1.5 million in Q2 2023, driven by increased headcount and clinical and AI-related costs.
- Net loss for Q2 2024 was $5 million, up from $3.2 million in Q2 2023.
- The company is still in the process of addressing a small number of remaining questions from the FDA for AIMIGo's 510(k) submission.
- HeartBeam Inc (BEAT) anticipates a limited launch of AIMIGo by the end of 2024, which may delay broader market adoption and revenue generation.
Greetings, and welcome to the HeartBeam second-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded.
Before we begin the formal presentation, I would like to remind everyone that statements made on the call and webcast may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation.
Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important facts relating to our business that may affect our predictions. You should also review our most recent Form 10-K
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
